After months of deliberation, the U.S. Federal Trade Commission has voted unanimously to investigate several of the largest pharmacy benefit managers, a collection of behind-the-scenes companies that have an outsized, but little-understood role in the cost of prescription medicines.
The probe will examine several controversial practices that have placed a harsh spotlight on these pharmaceutical industry middlemen, which serve as linchpins in the complex pharmaceutical supply chain. Through their unique position, pharmacy benefit managers help determine which medicines are covered by commercial health insurers and prices paid at pharmacy counters, among other things.
Continue to STAT+ to read the full story…
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
